指南与共识

仅肿瘤测序的胚系聚焦分析:ESMO精准医学工作组的推荐

Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
指南 / 共识 · Ann Oncol · 2019-01-01

ESMO精准医学工作组胚系亚组基于17152例肿瘤样本的配对测序数据,在65个癌症易感基因中鉴定出1494个致病性序列变异,据此提出仅肿瘤测序数据的胚系聚焦分析推荐、胚系后续检测指征及患者知情同意指导。

要点

  • 仅肿瘤测序发现的癌症易感基因致病性变异,常难区分体细胞或胚系来源。
  • 工作组基于17152例肿瘤样本、65个易感基因中1494个致病性变异提出推荐。
  • 推荐涵盖胚系聚焦分析、胚系后续检测指征及患者知情与同意指导。

核心结论

  • ESMO精准医学工作组胚系亚组基于配对测序分析,提出了仅肿瘤测序数据胚系聚焦分析、胚系后续检测指征及患者知情同意的推荐。

研究设计与样本

  • ESMO精准医学工作组胚系亚组对17152例癌症样本的配对测序数据进行分析,在65个癌症易感基因中鉴定出1494个致病性序列变异。

主要发现

  • 配对测序数据来自17152例癌症样本,在65个癌症易感基因中鉴定出1494个致病性序列变异。
  • 仅肿瘤测序中癌症易感基因的致病性序列变异,常难以判断为体细胞还是胚系来源。
  • 系统开展胚系聚焦分析的程度及对哪些变异进行胚系样本后续分析,存在广泛差异。

关键数值与推荐

  • 工作组就仅肿瘤测序数据的胚系聚焦分析提出推荐。
  • 工作组就胚系后续检测的指征提出推荐。
  • 工作组就患者信息告知与知情同意提出指导。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is increasingly common in oncology practice to perform tumour sequencing using large cancer panels. For pathogenic sequence variants in cancer susceptibility genes identified on tumour-only sequencing, it is often unclear whether they are of somatic or constitutional (germline) origin. There is wide-spread disparity regarding both the extent to which systematic 'germline-focussed analysis' is carried out upon tumour sequencing data and for which variants follow-up analysis of a germline sample is carried out. Here we present analyses of paired sequencing data from 17 152 cancer samples, in which 1494 pathogenic sequence variants were identified across 65 cancer susceptibility genes. From these analyses, the European Society of Medical Oncology Precision Medicine Working Group Germline Subgroup has generated (i) recommendations regarding germline-focussed analyses of tumour-only sequencing data, (ii) indications for germline follow-up testing and (iii) guidance on patient information-giving and consent.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Mandelker D, Donoghue M, Talukdar S, et al. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group. Ann Oncol. 2019. PMID: 31050713. doi:10.1093/annonc/mdz136

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。